BCPEM
SGMO

Bain Capital Public Equity Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bain Capital Public Equity Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-140,992
Closed -$2M – 76
2018
Q2 		$2M Buy
+140,992
New +$2.34M 0.14% 52
2018
Q1 		– Sell
-128,184
Closed -$2.1M – 97
2017
Q4 		$2.1M Sell
128,184
-75,607
-37% -$1.12M 0.15% 58
2017
Q3 		$3.06M Buy
+203,791
New +$2.25M 0.19% 49

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bain Capital Public Equity Management's SGMO Position: Q3 2018 in Review

Bain Capital Public Equity Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2018, closing a stake of 140,992 shares — an estimated $2M sold.

Bain Capital Public Equity Management first reported a position in SGMO in Q3 2017 and held it in 3 quarters. The position peaked at $3.06M in Q3 2017. 217 funds tracked by Wall St. Rank hold SGMO as of Q3 2018.

  • Bain Capital Public Equity Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2018 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 140,992 SANGAMO THERAPEUTICS INC shares in Q3 2018, an estimated $2M.
  • Bain Capital Public Equity Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 3 quarters.
  • Bain Capital Public Equity Management's SANGAMO THERAPEUTICS INC position peaked at $3.06M in Q3 2017.
  • 217 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2018.

Based on Bain Capital Public Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.